A Phase I/II, open-label, single arm, two-stage trial to evaluate the single and multi-dose PK and safety of DTG in HIV-exposed neonates on ARV prophylaxis. HIV-exposed term neonates born mothers with HIV on DTG-based antiretroviral therapy with a birth weight ≥2000 g who are on ARV postnatal prophylaxis will be enrolled.~Enrolment will be in two stages:~Stage 1 will assess a single 5 mg dose of the DTG dispersible tablet in two sequential cohorts: Cohort 1A (n=8) and Cohort 1B (n=8).~Stage 2 will assess multiple 5 mg doses of the DTG dispersible tablet in a single cohort: Cohort 2 (n=24).~Per national guidelines, all infants receive a birth HIV nucleic acid test (NAT). HIV NAT test results for the infant may or may not be available (HIV pending) at the time of study entry. HIV NAT results are typically available within 72 hours of the blood sample being taken and are checked and acted upon by the hospital HIV PMTCT service, as part of standard of care. If an HIV NAT result comes back positive whilst the neonate is on study, the neonate will not receive any further DTG doses, revert to standard of care antiretroviral therapy (ART), and be followed for safety for the duration of the study.~Primary Objectives:~To evaluate the pharmacokinetics of dolutegravir (DTG) during the first 28 days of life in HIV-exposed term neonates (born to a mother with HIV) following administration of DTG dispersible tablet~To determine the safety of DTG during the first 28 days of life in HIV-exposed term neonates following administration of DTG dispersible tablet~Secondary Objectives:~• To assess the acceptability of DTG dispersible tablet for the neonate and the caregiver~Primary endpoints:~DTG plasma pharmacokinetics parameters: area under the concentration time curve (AUC); maximum plasma concentration (Cmax), apparent clearance (CL/F), and trough concentration (Ctrough)~Occurrence of the following events: adverse events of Grade 3 or higher; treatment-related adverse events of Grade 3 or higher; any adverse events~Secondary endpoints:~• Acceptability to caregivers and neonates of using DTG-DT will be measured by means of a questionnaire
A Phase I/II, open-label, single arm, two-stage trial to evaluate the single and multi-dose PK and safety of DTG in HIV-exposed neonates on ARV prophylaxis. HIV-exposed term neonates born mothers with HIV on DTG-based antiretroviral therapy with a birth weight ≥2000 g who are on ARV postnatal prophylaxis will be enrolled.